News

Replimune surges as Cantor upgrades on possible FDA U-turn on lead drug

Replimune (NASDAQ:REPL) stock surges as Cantor Fitzgerald upgrades, citing improved odds for approval of its lead drug after an FDA leadership change. Read more here.

Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs

Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics ...

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection Of Melanoma Drug - Hagens Berman

The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA) had rejected its ...
Sport.co.uk7d

Transfer rumors, news: Liverpool turn to Gordon as Diaz replacement

Liverpool are looking to re-ignite interest in Newcastle winger Anthony Gordon if Luis Díaz leaves this summer. Transfe ...

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.
Developer Tech9d

Python 3.14 slithers closer with RC1 arrival

The Python development team has announced the arrival of 3.14's first release candidate before its official launch in October ...
Investor's Business Daily on MSN10d

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...